Registered title, quoted from ClinicalTrials.gov
Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Harbin Medical University Cancer Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07752550, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 100 years; sex: women only
Registered eligibility fields
Available tissue sample for testing, and gBRCA1/2 mutation status must be determined prior to treatment;
Inclusion criterion 7
Received other anti-tumor therapy within 4 weeks prior to the first dose of study drug;
Exclusion criterion 2
Prior treatment with tumor immunotherapy (including but not limited to PD-1, PD-L1, CTLA-4 inhibitors, etc.) or TGF-β inhibitors;
Exclusion criterion 3
Prior treatment with PARP inhibitors (except for patients who completed PARP inhibitor therapy for ovarian cancer ≥5 years ago with no recurrence or metastasis);
Exclusion criterion 4
Underwent major surgery unrelated to breast cancer within 4 weeks prior to enrollment, or have not fully recovered from such surgery;
Exclusion criterion 6
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
Inclusion criterion 6
At least one measurable lesion per RECIST version 1.1 criteria;
Inclusion criterion 3
Congenital or acquired immunodeficiency (e.g., HIV-infected patients);
Exclusion criterion 9
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07752550, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age ≥18 years, female;
- Histopathologically confirmed recurrent or metastatic triple-negative breast cancer, defined as ER-negative (IHC ER-positive percentage <1%), PR-negative (IHC PR-positive percentage <1%), and HER2-negative (IHC -/+ or IHC ++ but FISH/CISH -);
- At least one measurable lesion per RECIST version 1.1 criteria;
- Advanced cohort:
Metastatic or unresectable locally advanced TNBC (no prior systemic therapy or completed neoadjuvant/adjuvant therapy ≥12 months); PD-L1 positive with a Combined Positive Score (CPS) ≥1;
Neoadjuvant cohort:
Clinical stage II (T2N0-1M0/T3N0M0) or III (T2N2-3M0/T3N1-3M0) previously untreated breast cancer patients;
- Life expectancy ≥3 months;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- Available tissue sample for testing, and gBRCA1/2 mutation status must be determined prior to treatment;
- Adequate major organ function meeting the following criteria (no blood transfusion or use of granulocyte colony-stimulating factor or thrombopoietin within 2 weeks prior to screening):
Hematologic: Absolute neutrophil count (ANC) ≥1.5×10⁹/L; platelet count (PLT) ≥90×10⁹/L; hemoglobin (Hb) ≥90 g/L; Biochemical: Total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); ALT and AST ≤1.5× ULN (≤3× ULN for patients with liver metastases); alkaline phosphatase ≤2.5× ULN; BUN and creatinine ≤1.5× ULN with creatinine clearance ≥50 mL/min (calculated by Cockcroft-Gault formula); Thyroid-stimulating hormone (TSH) ≤ULN (if abnormal, T3 and T4 levels should also be assessed; patients with normal T3 and T4 levels may be enrolled); Echocardiography: Left ventricular ejection fraction (LVEF) ≥50%; 18-lead electrocardiogram: Fridericia-corrected QT interval (QTcF) <480 ms for females;
- Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment and agree to use adequate contraception during the study period and for at least 4 months after the last dose of study drug;
- Willing to participate, capable of providing signed informed consent, and compliant with study procedures.
Exclusion Criteria:
- Concurrently receiving anti-tumor therapy in another clinical trial;
- Received other anti-tumor therapy within 4 weeks prior to the first dose of study drug;
- Prior treatment with tumor immunotherapy (including but not limited to PD-1, PD-L1, CTLA-4 inhibitors, etc.) or TGF-β inhibitors;
- Prior treatment with PARP inhibitors (except for patients who completed PARP inhibitor therapy for ovarian cancer ≥5 years ago with no recurrence or metastasis);
- Untreated active brain metastases or leptomeningeal metastases;
- Underwent major surgery unrelated to breast cancer within 4 weeks prior to enrollment, or have not fully recovered from such surgery;
- Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism); patients with vitiligo or childhood asthma that has completely resolved and does not require any intervention in adulthood may be included; patients with asthma requiring bronchodilator therapy for medical intervention are excluded;
- Severe cardiac disease or conditions, including but not limited to: documented history of heart failure or systolic dysfunction (LVEF <50%); uncontrolled high-risk arrhythmias, such as atrial tachycardia, resting heart rate >100 bpm, significant ventricular arrhythmias (e.g., ventricular tachycardia), or high-grade atrioventricular block (i.e., Mobitz II second-degree or third-degree atrioventricular block); angina requiring anti-anginal medication; clinically significant valvular heart disease; ECG showing transmural myocardial infarction; poorly controlled hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg);
- Congenital or acquired immunodeficiency (e.g., HIV-infected patients);
- Received live vaccine within 4 weeks prior to study drug administration or likely to receive such vaccine during the study period;
- Known hypersensitivity to any component of the study drugs in this protocol;
- Severe concomitant disease or other comorbidities that may interfere with the planned treatment, or any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in this study.
Quoted from ClinicalTrials.gov, NCT07752550, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07752550, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.